| Primary |
| Lung Neoplasm Malignant |
54.0% |
| Non-small Cell Lung Cancer |
17.6% |
| Nausea |
3.8% |
| Pain |
2.6% |
| Neoplasm Malignant |
2.5% |
| Bronchial Carcinoma |
2.4% |
| Anxiety |
1.8% |
| Lung Cancer Metastatic |
1.7% |
| Lung Cancer |
1.7% |
| Tracheal Cancer |
1.5% |
| Hypertension |
1.4% |
| Lung Adenocarcinoma |
1.3% |
| Depression |
1.2% |
| Non-small Cell Lung Cancer Metastatic |
1.1% |
| Lung Carcinoma Cell Type Unspecified Stage Iv |
1.1% |
| Cancer Pain |
0.9% |
| Non-small Cell Lung Cancer Stage Iv |
0.9% |
| Constipation |
0.9% |
| Vomiting |
0.9% |
| Prophylaxis |
0.7% |
|
| Death |
24.4% |
| Lung Neoplasm Malignant |
13.4% |
| Vomiting |
11.0% |
| Nausea |
5.3% |
| Disease Progression |
4.4% |
| Neoplasm Malignant |
4.4% |
| Visual Impairment |
4.4% |
| Oedema Peripheral |
4.1% |
| Non-small Cell Lung Cancer |
3.9% |
| Diarrhoea |
3.6% |
| Interstitial Lung Disease |
2.7% |
| Constipation |
2.6% |
| Fatigue |
2.6% |
| Vision Blurred |
2.5% |
| Vitreous Floaters |
2.0% |
| Off Label Use |
1.9% |
| Dyspepsia |
1.8% |
| Malaise |
1.8% |
| Dyspnoea |
1.6% |
| Oedema |
1.6% |
|
| Secondary |
| Lung Neoplasm Malignant |
31.9% |
| Non-small Cell Lung Cancer |
18.9% |
| Product Used For Unknown Indication |
6.3% |
| Nausea |
6.0% |
| Bronchial Carcinoma |
4.9% |
| Pain |
4.4% |
| Hypertension |
4.1% |
| Adenocarcinoma |
2.6% |
| Tracheal Cancer |
2.4% |
| Blood Alkaline Phosphatase |
2.0% |
| Cancer Pain |
2.0% |
| Lung Cancer Metastatic |
2.0% |
| Anxiety |
1.9% |
| Depression |
1.9% |
| Lung Adenocarcinoma |
1.7% |
| Bronchial Neoplasm |
1.5% |
| Endocrine Disorder |
1.5% |
| Prophylaxis |
1.5% |
| Constipation |
1.4% |
| Blood Cholesterol Abnormal |
1.0% |
|
| Vomiting |
20.0% |
| Death |
9.0% |
| Interstitial Lung Disease |
8.0% |
| Visual Impairment |
6.0% |
| Non-small Cell Lung Cancer |
5.5% |
| Oedema Peripheral |
5.5% |
| Vision Blurred |
5.0% |
| Lung Neoplasm Malignant |
4.5% |
| Nausea |
4.5% |
| Weight Increased |
4.5% |
| Disease Progression |
4.0% |
| Pulmonary Embolism |
4.0% |
| Malaise |
3.0% |
| Off Label Use |
3.0% |
| Constipation |
2.5% |
| Liver Function Test Abnormal |
2.5% |
| Pneumonia |
2.5% |
| Cardio-respiratory Arrest |
2.0% |
| Diarrhoea |
2.0% |
| Dysgeusia |
2.0% |
|
| Concomitant |
| Lung Carcinoma Cell Type Unspecified Stage 0 |
66.7% |
| Arthritis |
33.3% |
|
| Macular Degeneration |
33.3% |
| Malignant Neoplasm Progression |
33.3% |
| Pyrexia |
33.3% |
|
| Interacting |
| Lung Neoplasm Malignant |
21.5% |
| Blood Alkaline Phosphatase |
19.4% |
| Abdominal Discomfort |
12.9% |
| Gastrooesophageal Reflux Disease |
12.9% |
| Nausea |
8.6% |
| Vomiting |
7.5% |
| Asthma |
6.5% |
| Convulsion |
6.5% |
| Back Pain |
1.1% |
| Non-small Cell Lung Cancer |
1.1% |
| Non-small Cell Lung Cancer Metastatic |
1.1% |
| Prophylaxis |
1.1% |
|
| Vomiting |
70.0% |
| Nausea |
20.0% |
| Somnolence |
10.0% |
|
